Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523549 · ClinicalTrials.gov registry record · Phase 4
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 229
- Enrollment target
NCT00523549: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT00523549 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 229 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00523549, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 229 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.
Primary Outcome
Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24
Interventions
- DRUG valsartan
- DRUG amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
What the finished NCT00523549 record still lists
NCT00523549 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which valsartan is the first listed.
NCT00523549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00523549 about?
NCT00523549 is a clinical study titled "The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction". The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties o...
What is the current status of trial NCT00523549?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 229 participants. The study started on 2006-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00523549?
The interventions under investigation include: valsartan (DRUG), amlodipine (DRUG).
Who is sponsoring clinical trial NCT00523549?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00523549's enrollment target sits among peer trials
229 374th of 2000 higher than 1,627 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia